Drug Approval | August 03, 2021
AYUSH 64 effective in mild and moderate COVID 19
It works as an adjunct to standard care based on robust clinical trials
It works as an adjunct to standard care based on robust clinical trials
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company is confident of commencing production at both Mahad and Chiplun units soon
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated
